Rainbow Childrens Medicare Ltd.
RAINBOWHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
18 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 18 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220603 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220817 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221111 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230217 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230522 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230816 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231107 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240201 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240527 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240821 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241104 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250215 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250531 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250804 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251120 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260203 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260601 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260804 | 2026-06-30 | yes |
RAINBOW
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,412.60 |
| 52-week range | 1103.8 – 1598.6 |
| Return 1M | -2.26% |
| Return 3M | -1.53% |
| Return 1Y | 1.47% |
| Return 3Y | 36.62% |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 470.00 |
| Other income | 13.00 |
| Total income | 483.00 |
| Cost of materials consumed | 65.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 0.00 |
| Employee benefit expense | 67.00 |
| Finance costs | 21.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.50 | 0.00 |
| institutions foreign | 0.16 | -0.01 |
| institutions domestic | 0.23 | 0.01 |
| mutual funds | 0.19 | 0.01 |
| public | 0.50 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 18 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 313.00 | 306.00 | 317.00 | 287.00 | 333.00 | 336.00 | 341.00 | 330.00 | 417.00 | 398.00 | 370.00 | 353.00 | 445.00 | 445.00 | 460.00 | 470.00 |
| Other income | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 9.00 | 13.00 | 12.00 | 11.00 | 13.00 | 15.00 | 20.00 | 8.00 | 11.00 | 5.00 | 13.00 |
| Total income | 321.00 | 315.00 | 326.00 | 295.00 | 340.00 | 345.00 | 354.00 | 342.00 | 429.00 | 411.00 | 385.00 | 373.00 | 453.00 | 456.00 | 465.00 | 483.00 |
| Cost of materials consumed | 44.00 | 40.00 | 43.00 | 38.00 | 42.00 | 43.00 | 42.00 | 42.00 | 52.00 | 54.00 | 47.00 | 47.00 | 62.00 | 60.00 | 57.00 | 65.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 34.00 | 38.00 | 41.00 | 44.00 | 41.00 | 43.00 | 48.00 | 49.00 | 54.00 | 49.00 | 54.00 | 52.00 | 59.00 | 60.00 | 63.00 | 67.00 |
| Finance costs | 13.00 | 14.00 | 14.00 | 15.00 | 13.00 | 14.00 | 17.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 19.00 | 20.00 | 20.00 | 21.00 |
| Depreciation and amortisation | 22.00 | 23.00 | 23.00 | 25.00 | 27.00 | 28.00 | 32.00 | 34.00 | 35.00 | 35.00 | 34.00 | 34.00 | 36.00 | 40.00 | 41.00 | 42.00 |
| Other expenses | 126.00 | 121.00 | 136.00 | 117.00 | 132.00 | 132.00 | 145.00 | 145.00 | 165.00 | 161.00 | 154.00 | 150.00 | 175.00 | 178.00 | 195.00 | 204.00 |
| Total expenses | 239.00 | 236.00 | 256.00 | 239.00 | 255.00 | 260.00 | 285.00 | 289.00 | 323.00 | 317.00 | 308.00 | 302.00 | 351.00 | 358.00 | 377.00 | 399.00 |
| Profit before exceptional items and tax | 81.00 | 78.00 | 70.00 | 56.00 | 85.00 | 85.00 | 69.00 | 53.00 | 105.00 | 94.00 | 77.00 | 71.00 | 102.00 | 98.00 | 88.00 | 84.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 |
| Profit before tax | 81.00 | 78.00 | 70.00 | 56.00 | 85.00 | 85.00 | 69.00 | 53.00 | 105.00 | 94.00 | 77.00 | 71.00 | 102.00 | 98.00 | 87.00 | 84.00 |
| Current tax | 24.00 | 23.00 | 21.00 | 16.00 | 24.00 | 24.00 | 14.00 | 16.00 | 29.00 | 25.00 | 20.00 | 17.00 | 29.00 | 24.00 | 26.00 | 22.00 |
| Deferred tax | -4.00 | -3.00 | -5.00 | -2.00 | -2.00 | -1.00 | 4.00 | -2.00 | -3.00 | 1.00 | 1.00 | 0.00 | -3.00 | -0.00 | -17.00 | -1.00 |
| Tax expense | 20.00 | 20.00 | 16.00 | 14.00 | 22.00 | 22.00 | 18.00 | 14.00 | 26.00 | 25.00 | 20.00 | 18.00 | 27.00 | 24.00 | 9.00 | 21.00 |
| Profit for the period | 62.00 | 58.00 | 54.00 | 41.00 | 63.00 | 63.00 | 51.00 | 40.00 | 79.00 | 69.00 | 57.00 | 54.00 | 76.00 | 74.00 | 78.00 | 63.00 |
| Profit attributable to owners | 61.00 | 58.00 | 54.00 | 41.00 | 63.00 | 62.00 | 51.00 | 40.00 | 79.00 | 69.00 | 56.00 | 53.00 | 75.00 | 73.00 | 77.00 | 61.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 |
| Other comprehensive income | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 1.00 | -4.00 | 3.00 | -0.00 | -0.00 | -0.00 | -1.00 | -0.00 |
| Total comprehensive income | 62.00 | 58.00 | 54.00 | 42.00 | 63.00 | 63.00 | 52.00 | 40.00 | 80.00 | 65.00 | 60.00 | 54.00 | 76.00 | 74.00 | 78.00 | 62.00 |
| Earnings per share, basic | 6.06 | 5.74 | 5.31 | 4.04 | 6.20 | 6.12 | 5.02 | 3.89 | 7.77 | 6.76 | 5.55 | 5.27 | 7.41 | 7.14 | 7.59 | 5.97 |
| Earnings per share, diluted | 6.06 | 5.74 | 5.31 | 4.04 | 6.20 | 6.12 | 5.02 | 3.89 | 7.77 | 6.76 | 5.55 | 5.27 | 7.41 | 7.14 | 7.59 | 5.97 |
Annual results, as filed
| Line | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 974.00 | 1,174.00 | 1,297.00 | 1,516.00 | 1,703.00 |
| Other income | 19.00 | 31.00 | 37.00 | 51.00 | 44.00 |
| Total income | 993.00 | 1,204.00 | 1,334.00 | 1,567.00 | 1,747.00 |
| Cost of materials consumed | 195.00 | 158.00 | 165.00 | 195.00 | 227.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 116.00 | 144.00 | 176.00 | 206.00 | 234.00 |
| Finance costs | 53.00 | 55.00 | 59.00 | 72.00 | 78.00 |
| Depreciation and amortisation | 83.00 | 90.00 | 112.00 | 138.00 | 151.00 |
| Other expenses | 358.00 | 475.00 | 527.00 | 625.00 | 698.00 |
| Total expenses | 805.00 | 923.00 | 1,039.00 | 1,237.00 | 1,387.00 |
| Profit before exceptional items and tax | 187.00 | 282.00 | 295.00 | 330.00 | 360.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 |
| Profit before tax | 187.00 | 282.00 | 295.00 | 330.00 | 358.00 |
| Current tax | 58.00 | 84.00 | 77.00 | 89.00 | 96.00 |
| Deferred tax | -9.00 | -15.00 | -1.00 | -4.00 | -19.00 |
| Tax expense | 49.00 | 69.00 | 77.00 | 86.00 | 77.00 |
| Profit for the period | 139.00 | 212.00 | 218.00 | 244.00 | 282.00 |
| Profit attributable to owners | 138.00 | 211.00 | 217.00 | 243.00 | 278.00 |
| Profit attributable to non-controlling interests | 0.00 | 2.00 | 1.00 | 1.00 | 3.00 |
| Other comprehensive income | 1.00 | 0.00 | 1.00 | -0.00 | -1.00 |
| Total comprehensive income | 140.00 | 213.00 | 220.00 | 244.00 | 281.00 |
| Earnings per share, basic | 14.75 | 20.89 | 21.38 | 23.97 | 27.41 |
| Earnings per share, diluted | 14.75 | 20.89 | 21.38 | 23.84 | 27.41 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1,636.00 | 1,776.00 | 1,898.00 | 2,170.00 | 2,262.00 | 2,377.00 | 2,587.00 | 2,775.00 |
| Non-current assets | 1,271.00 | 1,293.00 | 1,339.00 | 1,549.00 | 1,576.00 | 1,545.00 | 1,844.00 | 2,112.00 |
| Current assets | 365.00 | 484.00 | 559.00 | 622.00 | 685.00 | 832.00 | 742.00 | 663.00 |
| Property, plant and equipment | 873.00 | 928.00 | 971.00 | 1,249.00 | 1,403.00 | 1,388.00 | 1,451.00 | 1,562.00 |
| Capital work-in-progress | 29.00 | 21.00 | 69.00 | 14.00 | 17.00 | 28.00 | 53.00 | 76.00 |
| Goodwill | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 158.00 | 157.00 |
| Other intangible assets | 2.00 | 3.00 | 3.00 | 4.00 | 10.00 | 10.00 | 40.00 | 37.00 |
| Inventories | 20.00 | 19.00 | 17.00 | 24.00 | 28.00 | 28.00 | 40.00 | 42.00 |
| Trade receivables | 63.00 | 58.00 | 65.00 | 70.00 | 95.00 | 77.00 | 107.00 | 103.00 |
| Cash and cash equivalents | 122.00 | 15.00 | 13.00 | 10.00 | 15.00 | 20.00 | 27.00 | 34.00 |
| Total equity and liabilities | 1,636.00 | 1,776.00 | 1,898.00 | 2,170.00 | 2,262.00 | 2,377.00 | 2,587.00 | 2,775.00 |
| Equity | 951.00 | 1,065.00 | 1,145.00 | 1,265.00 | 1,350.00 | 1,475.00 | 1,533.00 | 1,664.00 |
| Equity share capital | 102.00 | 102.00 | 102.00 | 102.00 | 102.00 | 102.00 | 102.00 | 102.00 |
| Other equity | 845.00 | 958.00 | 1,038.00 | 1,157.00 | 1,242.00 | 1,367.00 | 1,416.00 | 1,547.00 |
| Total liabilities | 685.00 | 711.00 | 753.00 | 905.00 | 912.00 | 902.00 | 1,054.00 | 1,111.00 |
| Non-current liabilities | 556.00 | 567.00 | 626.00 | 756.00 | 753.00 | 751.00 | 845.00 | 927.00 |
| Current liabilities | 129.00 | 144.00 | 127.00 | 149.00 | 160.00 | 151.00 | 208.00 | 184.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 77.00 | 84.00 | 75.00 | 81.00 | 101.00 | 91.00 | 129.00 | 101.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 149.00 | 327.00 | 152.00 | 321.00 | 193.00 | 396.00 | 208.00 | 420.00 |
| Net cash from investing activities | -210.00 | -465.00 | -92.00 | -226.00 | -114.00 | -268.00 | -125.00 | -259.00 |
| Net cash from financing activities | 172.00 | 143.00 | -64.00 | -102.00 | -73.00 | -118.00 | -76.00 | -147.00 |
| Purchase of property, plant and equipment | 60.00 | 141.00 | 243.00 | 354.00 | 80.00 | 146.00 | 302.00 | 216.00 |
| Net increase in cash | 112.00 | 5.00 | -4.00 | -7.00 | 5.00 | 10.00 | 7.00 | 14.00 |
| con:CFO.BEFORE_TAX | 186.00 | 408.00 | 192.00 | 410.00 | 234.00 | 481.00 | 252.00 | 521.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 37.00 | 81.00 | 40.00 | 89.00 | 41.00 | 86.00 | 44.00 | 102.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 203.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 49.83 | 49.83 | 49.83 | 49.83 | 49.83 | 49.88 | 49.85 | 49.85 | 49.85 | 49.85 | 0.50 | 0.50 | 0.50 | 0.50 |
| Domestic institutions | 15.38 | 15.35 | 15.40 | 15.62 | 14.76 | 13.80 | 13.83 | 13.87 | 15.31 | 15.44 | 0.17 | 0.19 | 0.21 | 0.23 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 11.28 | 0.13 | 0.15 | 0.17 | 0.19 |
| Insurance companies | 2.06 | 2.37 | 2.32 | 1.97 | 1.95 | 1.88 | 1.92 | 1.66 | 1.71 | 2.00 | 0.02 | 0.02 | 0.02 | 0.03 |
| Foreign institutions | 19.82 | 20.19 | 21.63 | 22.32 | 24.04 | 24.78 | 25.11 | 25.12 | 23.69 | 23.59 | 0.22 | 0.19 | 0.17 | 0.16 |
| Public | 50.17 | 50.17 | 50.17 | 50.17 | 50.17 | 50.12 | 50.15 | 50.15 | 50.15 | 50.15 | 0.50 | 0.50 | 0.50 | 0.50 |
| Non-institutional | 14.97 | 14.63 | 13.14 | 12.23 | 11.37 | 11.54 | 11.20 | 11.16 | 11.14 | 11.11 | 0.11 | 0.11 | 0.12 | 0.11 |
| Shares outstanding | 101501687 | 101501687 | 101501687 | 101501687 | 101501687 | 101501687 | 101551673 | 101551673 | 101551673 | 101551673 | 101559156 | 101559156 | 101559156 | 101559156 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Rosewalk Healthcare Private Limited | Wholly Owned Subsidiary | Any other transaction, Inter-corporate deposit, Purc | 58,690,000.00 | 7 |
| Dr. Ramesh Kancharla | Chairman and Managing Director | Any other transaction, Remuneration | 24,500,000.00 | 2 |
| Unimed Healthcare Private Limited | Enterprises where relative of key | Any other transaction | 24,300,000.00 | 2 |
| Mr. Sanjeev Sukumaran | Chief Operating Officer | Any other transaction, Remuneration | 15,490,000.00 | 2 |
| Dr. Dinesh Kumar Chirla | Whole Time Director | Purchase of goods or services | 13,350,000.00 | 1 |
| Mr.Vikas Maheshwari | Chief Financial Officer | Any other transaction, Remuneration | 10,080,000.00 | 2 |
| Dr. Nageswar Rao Koneti | Non-Executive Director | Purchase of goods or services | 7,500,000.00 | 1 |
| Rainbow Children's Foundation | Enterprises where key managerial p | Sale of goods or services | 6,660,000.00 | 2 |
| Rainbow Speciality Hospitals Private Limited | Subsidiary | Purchase of goods or services, Sale of goods or serv | 5,320,000.00 | 2 |
| Mr. Ramadhara Naidu Kancharla | Brother of Key Managerial Personne | Purchase of goods or services | 3,000,000.00 | 1 |
| Mr. Ashish Kapil | Company Secretary | Remuneration | 2,320,000.00 | 1 |
| Rainbow Children's Hospital Foundation | Enterprises where key managerial p | Any other transaction | 1,820,000.00 | 1 |
| Ravindranath GE Medical Associates Private Limited | Enterprises where key managerial p | Purchase of goods or services | 1,260,000.00 | 1 |
| Mr. Santanu Mukherjee | Independent Director | Any other transaction | 1,100,000.00 | 3 |
| Dr. Anil Dhawan | Independent Director | Any other transaction | 900,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-04 | Q1FY27 | Read the call | |
| 2026-06-01 | Q4FY26 | Read the call | |
| 2026-02-03 | Q3FY26 | Read the call | |
| 2025-11-20 | Q2FY26 | Read the call | |
| 2025-08-04 | Q1FY26 | Read the call | |
| 2025-05-31 | FYFY25 | Read the call | |
| 2025-02-15 | Read the call | ||
| 2024-11-04 | Q2FY25 | Read the call | |
| 2024-08-21 | Q1FY25 | Read the call | |
| 2024-05-27 | FYFY24 | Read the call | |
| 2024-02-01 | MANAGING DIRECTOR, OFFICER, OPERATING OFFICER | Read the call | |
| 2023-11-07 | H1FY24 | Read the call | |
| 2023-08-16 | Q1FY24 | Read the call | |
| 2023-05-22 | Q4FY23 | Read the call | |
| 2023-02-17 | Read the call | ||
| 2022-11-11 | H1FY23 | Read the call | |
| 2022-08-17 | Q1FY23 | Read the call | |
| 2022-06-03 | Q4FY22 | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY26 | Q1FY27 | Q2FY25 | Q2FY26 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | And sir, what kind of capex would we be incurring for this 150-bed greenfield hospital? | This view is based on our historical growth trajectory, the planned pace of capacity additions, and the geographies into which we are expanding. | Additionally, we primarily manage beds, which means a significant amount of money flows back to the owners in the form of rent and other costs Our cap… | What capex curve bed should we project going forward? | We have finalized our marketing and digital strategy, and we are also planning significant capital expenditure to evolve into a “digital front-door” h… | Number two how scalable is this business model and hospital scalability is the concern many are having and because of which the growth factor in hospi… | 35 crores as capital expenditure towards new projects, medical equipment and other fixed assets. | To date, all our expansion and capital expenditure programs have been funded through internal accruals. |
| Capital allocation | So, between those 250 beds and an additional 100 from recent acquisition (Warangal), we’re looking at roughly 350 beds getting added this year, not co… | We have also increased our investments in digital patient acquisition to strengthen our direct-to- patient engagement capabilities. | — | After the acquisition, the entire management changed, and all insurance empanelment had to be redone. | At the time of acquisition, Guwahati was generating close to INR 8 crores per month in revenue. | When we go into kind of some acquisition, aligned acquisition comes in that we can build newer city. | Sir, my question is on the Gurugram acquisition that we have announced. | Our acquisition strategy will focus on opportunities where there is scalability, alignment with our clinical philosophy, and an attractive micro-marke… |
| Costs | — | — | — | — | — | — | — | — |
| Debt and cash | — | And what specific measures are being taken to manage the margins, ensure consistent cash flow and strengthen the balance sheet, especially areas that … | — | — | — | So, this year also we will generate because there is a cash surplus, we will generate operating cash flow. | It's about what, yield on, you’re talking the free cash flow yield? | Can you elaborate in detail on the framework being used for cash flow forecasting, interest rate risk ,,~ Rainb~ w• Children's ~.2~.P.!!.~- Rainbow Ch… |
| Demand | Yes, we’re adding beds now — with the recent acquisition and around 250 beds already in the pipeline expected to come into operations over the next 2 … | Firstly, now that we are on 1,862-odd beds operational and given the pipeline that we have -- we are looking for after the acquisitions, is it right t… | So can you talk a bit more about this new initiative in terms of what kind of demand you are seeing in the market? | There is both a need and a demand for such a facility. | Our pipeline remains strong, with the next phase of bed additions expected over the next 18 to 24 months. | So, the current year unlikely to be any major bed additions, if some projects which are in the pipeline may come, may come in the last quarter into bu… | We are adding additional space in this hospital to allow it to yield some more beds to cater to the demand. • These hospitals are expected to come int… | Similarly, the development pipeline of approximately 900 beds that we recently outlined in our presentation is expected to be funded through internal … |
| Guidance | We'll be maintaining our mid-teens revenue guidance for the next couple of years? | As a result, we expect our NICU and PICU services to become major drivers of the Mumbai business. | — | We have now obtained the required permissions and insurance approvals, so we expect to see an uptick from December onwards. | We expect ARPP to grow at around 5%–7% CAGR over the long term. | And FY23 we expect going to be be a normal year and I mean we have done well in FY22 but it's a very bouncy pitch. | Any guidance on the revenue and the margin front for FY ‘24? | Mr. Rahul Jeewani - IIFL Capital Services ,,~ Rainbo w• Children's ~~~)!~~-- •• BirthRighf 8Y RAINBOW HOSPITALS Y1>u1A,111Mto•S•ltCtb......,. of being… |
| Margin | Just wanted to know is there any EBITDA drag due to the new facilities this quarter? | And also that should we see going forward, like the operational efficiency improves we can reach the higher EBITDA margins from here as well? | We don't disclose the margin based on the maturity. | This year, our base business is strong, and our EBITDA is still robust, but occupancies are down by about 8% and revenue is down by around 10%–12%. | Also a follow-up on that, could you please give us the occupancy and margin details for each of these 3 hospitals during the quarter? | This hospital achieved EBITDA breakeven in the first year of operation because of good number of patients foot fall and we have invested very minium C… | 316 crores and has grown by 49.2% compared to the corresponding quarter of the last financial year. • EBITDA for Q4 FY ‘23 stood at INR. | — |
| People | — | — | At what utilization level does a hospital start becoming profitable? | Could you share whether MICU utilization improved in Q2 relative to Q1 and whether that was a meaningful driver for the ARPOB recovery and do you see … | We get just add that in terms of longer term, we are now below 50% utilization. | Utilization level, bed utilization can you please tell how much it expects to go up to? | And also, that effective utilization of the space, for what rent you pay is very low: as almost 40% of the rental space will be invisible because of l… | — |
| Pricing | So there has been no price hikes in the insurance compartment or cash tariff at all, this is purely pediatric... | Markets such as Gurugram and the broader NCR region have higher pricing points, which should support better realizations. | — | I actually want to know like you mentioned earlier, that a payor mix was roughly 52% insurance and 40% cash in Q1. Has that ratio changed meaningfully… | Outcomes will depend on factors such as competitive intensity and local pricing dynamics. | So, when you look at the total revenue that we do, about 30% of our revenue is outpatient, where the insurance price hike will not be applicable. | The entire price hike will be there in this current year. | Pricing increases also contribute to ARPOB growth on a year-on-year basis. |
| Revenue growth | — | The first quarter delivered strong growth, and while the base will naturally become higher going forward, we remain confident of delivering revenue gr… | So for the matured hospital, the revenue growth is tremendous, I understand, because of the occupancy. | I think we are at about 3.2% of the total topline this year. | And ARPOB growth at some stage, let's say, now we have already reached -- We're actually doing really well on ARPOB now. | So, what we were kind of growing before the pre-pandemic was year-on-year about 20%, both in terms of numbers as well as the top line, and EBITDA. | 316 crores, which is a growth of 49.2% compared to the INR. | The acquired units, primarily Guwahati and Warangal, contributed around 7%–8% of revenue growth, depending on the month. |